IP Library Granted Patent US 11,499,977
Granted Patent B2
US 11,499,977 · App. 17/725,388 · Granted Nov 15, 2022

Equipment and procedure for culturing, separating, and genetically modifying donor cells for reinfusion into a patient

Inventors: Stefan Miltenyi (Bergisch Gladbach, DE); Winfried Schimmelpfennig (Krakow am See, DE); Holger Lantow (Rostock, DE); Niklas Elmar Neuschaefer (Rostock, DE); Martin Biehl (St. Wendel, DE); Eiad Kabaha (Bonn, DE); Juergen Schulz (Jesteburg, DE)
Assignee: MILTENYI BIOTEC B.V. & CO. KG
G01N33/58A61M1/0209A61M1/3618A61M1/3633A61M1/3679A61M1/3692A61M1/3693A61M1/3696B01D15/3809B01D15/3885B01D21/26B03C1/002B03C1/027B03C1/032B03C1/034B03C1/0332B03C1/0335B03C1/288B04B1/12B04B5/00B04B5/04B04B5/0442B04B5/10B04B7/08B04B13/00C12M23/28C12M33/10C12M41/48C12M47/04C12N5/0018C12N5/0636C12N5/0646C12N5/0647C12N5/0669G01N35/0098A61M2202/0071A61M2202/0413A61M2202/0427A61M2202/10B01D21/262B01L3/5021B03C2201/18B03C2201/26B04B2005/0464B04B2013/006C12N2500/34C12N2501/998G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,499,977
App. No.
17/725,388
Granted
Nov 15, 2022
Kind
B2
Abstract

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder ( 42 ), a pump ( 64 ) and a plurality of valves ( 1 - 11 ) configured to at least partially control fluid flow through a fluid circuitry and a separation column ( 40 ) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

Claims (31)

1. A method for providing a cellular product enriched in target cells,

wherein the method is performed in a single use tubing set that comprises:

(1) a sample processing unit that includes an input port operably connected to a sample chamber, wherein the sample chamber comprises additional ports to supply fresh media and gasses to support culture of cells in the chamber;

(2) a sample separation unit that includes a magnetic separation column, and

(3) fluid circuitry that interconnects the sample processing unit and the sample separation unit so that cells can flow between the sample processing unit and the sample separation unit in either direction;

wherein the method performed in the single use tubing set comprises:

(a) installing the single use tubing set onto an apparatus that is configured to operate the sample processing unit, the sample separation unit, and the fluid circuitry;

(b) receiving a sample of cells through the input port into the sample processing unit;

(c) preparing the sample of cells in the sample processing unit;

(d) transferring the prepared cells from the sample processing unit to the sample separation unit;

(e) separate the prepared cells into target cells and non-target cells in the sample separation unit using the magnetic separation column, allowing non-target cells to pass to a waste container;

(f) transferring the separated target cells back to the sample processing unit;

(g) culturing the target cells with genetic material in the sample chamber, supplying gas and fresh media as needed for the culturing, thereby genetically modifying the cells;

(h) processing the genetically modified cells by washing and adjusting volume; and thereafter

(i) delivering the genetically modified cells as a cellular product to a product collection container;

wherein the single use tubing set constitutes a closed sterile system, whereby the cellular product delivered to the product collection container in step (i) is suitable for administration to a human patient in need thereof.

2. The method of claim 1 , wherein the apparatus operating the single use tubing set includes a holder for the magnetic separation column, a pump, and a plurality of valves that control fluid flow through the fluid circuitry and the separation column.

3. The method of claim 1 wherein the target cells are hematopoietic stem or progenitor cells, dendritic cells, NK-cells, B-cells or monocytes.

4. The method of claim 1 wherein the target cells are T cells.

5. The method of claim 1 , wherein the target cells are positive for one or more markers selected from CD133, CD34, CD3, CD4, 8, 56, 19, 14, CD141 (BDCA-3), CD303 (BDCA-2), CD304 (BDCA-4), CD144, CD10, (BDCA-1), NKp46, NKp80, CD45RO, CD45RA, CD137, CD25, and CD138.

6. The method of claim 1 wherein the preparing in step (c) includes separating the cell sample into white blood cells (WBC) and other cells by density in the sample processing unit.

7. The method of claim 1 , wherein the preparation in step (c) includes culturing the cell sample with one or more cytokines.

8. The method of claim 1 , wherein the separating in step (e) comprises retaining target cells labeled with magnetic particles in the separation column while non-target cells that are not labeled with magnetic particles pass into the waste container.

9. The method of claim 8 , wherein the target cells are labeled with magnetic particles by way of an antibody or other binding partner conjugated to the particle, wherein the antibody or binding partner selectively binds a cell surface antigen on the target cells.

10. The method of claim 1 , wherein the separating in step (e) comprises retaining non-target cells labeled with the magnetic particles in the separation column while target cells that are not labeled with magnetic particles pass into the sample processing unit.

11. The method of claim 10 , wherein the non-target cells are labeled with magnetic particles by way of an antibody or other binding partner conjugated to the particle, wherein the antibody or binding partner selectively binds a cell surface antigen on the non-target cells.

12. The method of claim 1 , wherein the genetic material cultured with the cells in the sample camber in step (g) is a DNA vector.

13. The method of claim 1 , wherein the cells are genetically modified in step (g) to express a T cell receptor.

14. The method of claim 1 , wherein the processing in step (h) comprises removing a volume of the cell culture medium, and resuspending the genetically modified cells in an infusion solution.

15. The method of claim 1 , wherein cells are monitored in the sample processing unit through a window or prism in the sample chamber.

16. The method of claim 2 , wherein the apparatus is operated by a computer that is programmed to direct flow of fluids through the fluid circuitry and the separation column, to control magnetic field strength of the separation column so as to retain and release magnetically labeled target cells, to manage the culturing of the target cells with the genetic material, and thereafter to deliver the cellular product into an output container for administration to the patient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2022
From: MILTENYI, STEFAN; SCHIMMELPFENNIG, WINFRIED; LANTOW, HOLGER; KABAHA, EIAD; NEUSCHAFER, ELMAR NIKLAS; BIEHL, MARTIN; SCHULZ, JURGEN
To: MILTENYI BIOTEC GMBH
Reel/Frame 060377/0115 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2022
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 060377/0148 →
Continuity (8)
Continuation 16889471 · Jun 1, 2020
Continuation 16675072 · Nov 5, 2019
Continuation 15706517 · Sep 15, 2017
Continuation 15395215 · Dec 30, 2016
Continuation 14181023 · Feb 14, 2014
Division 12745688
Provisional Application 61012361 · Dec 7, 2007
Related Publication 20220244264A1 · Aug 4, 2022
Cited By (1)
US 12,498,374